Table 1

Clinical characteristics of the study population

IFX-treated patients (n=250)Median age (IQR 25–75, range)52.5 (42–63, 21–82)
SexMale39.8%
Female60.2%
DiseaseRheumatoid arthritis43.5%
Spondyloarthritis56.5%
Mean IFX therapy, years (IQR 25–75, range)4.9 (1.8–7.8, 0.3–13.8)
ATI statusPositive49.6%
Negative50.4%
Concomitant immunosuppressivesNo23.1%
Methotrexate56.5%
Others*20.4%
Controls (IFX-naïve) (n=77)Rheumatic patients48.0%
Anti-adalimumab antibody-positive rheumatic patients24.7%
Healthy individuals27.3%
  • *Other concomitant immunosuppressives were sulfasalazine, prednisone, leflunomide, azathioprine and hydroxychloroquine alone or in combination.

  • ATI, antibodies to IFX IFX, infliximab.